BiotechTube

ACT-541468 5 mg + ACT-541468 10 mg + ACT-541468 25 mg + Zolpidem + Placebo 1 + Placebo 2

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Insomnia Disorder

Conditions

Insomnia Disorder

Trial Timeline

Oct 4, 2016 → Jun 20, 2017

NCT ID
NCT02839200

About ACT-541468 5 mg + ACT-541468 10 mg + ACT-541468 25 mg + Zolpidem + Placebo 1 + Placebo 2

ACT-541468 5 mg + ACT-541468 10 mg + ACT-541468 25 mg + Zolpidem + Placebo 1 + Placebo 2 is a phase 2 stage product being developed by Idorsia for Insomnia Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT02839200. Target conditions include Insomnia Disorder.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02839200Phase 2Completed

Competing Products

20 competing products in Insomnia Disorder

See all competitors
ProductCompanyStageHype Score
Zolpidem (Myslee®) + placeboAstellas PharmaApproved
85
zolpidemAstellas PharmaApproved
85
Mirtazapine TabletsSun PharmaceuticalApproved
85
Lemborexant (LEM) 5 mg (Z-Drug-mono cohort) + Lemborexant (LEM) 5 mg (SUV-mono cohort) + Lemborexant (LEM) 5 mg (SUV-combination cohort) + Lemborexant (LEM) 5 mg (RMT-combination cohort)EisaiApproved
85
E2006 1.0 mg + E2006 2.5 mg + E2006 5.0 mg + E2006 10.0 mg + E2006 25.0 mg + E2006 50.0 mg + E2006 100 mg + E2006 200 mg + Zolpidem 10 mg + E2006 Matched Placebo or Zolpidem Matched Placebo + E2006 Matched PlaceboEisaiPhase 1
33
Lemborexant 5 mg + Lemborexant 10 mg + Lemborexant-matched placebo. + Flurazepam 30 mgEisaiPhase 1
33
E2006EisaiPhase 1
33
Lemborexant + Lemborexant + Lemborexant-matched placebo + Zolpidem tartrate + Zolpidem-matched placeboEisaiPhase 3
77
LEM 5 mg + LEM 10 mgEisaiPhase 3
77
EszopicloneEisaiPre-clinical
23
Eszopiclone 1 mg + Eszopiclone 2 mg + Eszopiclone 3 mg + Placebo + Zolpidem Tartrate 10 mgEisaiPhase 2/3
65
lemborexant + PlaceboEisaiPhase 3
77
E2006 + PlaceboEisaiPhase 2
52
Zolpidem tablets + Suvorexant tablets, over-encapsulated + Lemborexant tablets + Placebo lemborexant + Placebo zolpidem + Placebo suvorexantEisaiPhase 1
33
EszopicloneEisaiPre-clinical
23
Eszopiclone 1 mg- Elderly + Eszopiclone 2 mg- Elderly + Eszopiclone 3 mg- Non-elderly + Eszopiclone 2 mg- Non-elderlyEisaiPhase 3
77
Eszopiclone 3 mg + Eszopiclone 1 mgEisaiPhase 1
33
LY2624803Eli LillyPhase 1
33
LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - TabletsEli LillyPhase 1
33
LY2624803Eli LillyPhase 1
33

Other Products from Idorsia

Daridorexant + PlaceboApproved
80
Daridorexant 50 mg + PlaceboApproved
80
Aprocitentan 12.5 mg + Aprocitentan 25 mg + PlaceboPhase 3
72
LucerastatPhase 3
72
Clazosentan + PlaceboPhase 3
72